Abstract
As cytokines play key roles in physiological and pathophysiological processes, substantial research has been directed to identifying and elucidating the structures and functions of various cytokines and to understanding the processes that regulate them. Significant efforts have also been directed toward the identification of selective inhibitors of many of the cytokines (for review, see [1]).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Henderson B, Bodmer MW (eds) (1996)Therapeutic modulation of cytokines.CRC Press, Inc, Boca Raton, FL
Bennett CF, Crooke ST (1996) Oligonucleotide-based inhibitors of cytokine expression and function. In: B Henderson, M Bodmer (eds):Therapeutic modulation of cytokines.CRC Press, Inc, Boca Raton, FL, 171–193
Krieg AM (1998) Immune stimulation by oligonucleotides. In: ST Crooke (ed):Hand-book of experimental pharmacology: Antisense research and application.Springer-Verlag, Berlin, Heidelberg, 243–262
Neilsen PE (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide.Science254: 1497–1500
Mollegaard NE, Buchardt O, Egholm M, Nielsen PE (1994) PNA-DNA strand displacement loops as artificial transcription promoters.Proc Natl Acad Sci USA91: 3892–3895
Sun JS, Helene C (1993) Oligonucleotide-directed triple-helix formation.Curr Opin Struct Biol3(3): 345–356
Bielinska A, Shivdasani RA, Zhang L, Nabel GJ (1990) Regulation of gene expression with double-stranded phosphorothioate oligonucleotides.Science250: 997–1000
Stein CA, Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents-Is the bul-let really magical?Science261: 1004–1012
Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides.Nature372: 333–335
Crooke ST (1997) Advances in understanding the pharmacological properties of anti-sense oligonucleotides. In: B Weiss (ed):Antisense oligodeoxynucleotides and antisense RNA novel pharmacological and therapeutic agents.CRC Press, Boca Raton, 17–25
Wu H, Macleod AR, Lima WF, Crooke ST (1998) Identification and partial purification of human double strand RNase activity A novel terminating mechanism for oligoribonucleotide antisense drugs.J Biol Chem273 (5): 2532–2542
Crooke ST (1996) Advances in understanding the pharmacological properties of anti-sense oligonucleotides.Advances in Pharmacology40: 1–49
Crouch RJ, Dirksen M-L (1985) Ribonucleases H. In: SM Linn, RJ Roberts (eds):Nucleases.Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 211–241
Wu H, Lima WF, Crooke ST (1998) Molecular cloning and expression of cDNA for human RNase H.Antisense Nucleic Acid Drug Dev8(1): 53–61
Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. JBiol Chem266: 18162–18171
Dean NM, McKay R (1994) Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.Proc Natl Acad Sci USA91: 11762–11766
Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B (1994) Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.Proc Natl Acad Sci USA91: 4504–4508
Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM (1994) Biologic and therapeutic significance of MYB expression in human melanoma.Proc Natl Acad Sci USA91: 4499–4503
Greig MJ, Gaus H, Cummins LL, Sasmor H, Griffey RH (1995) Measurement of macro-molecular binding using electrospray mass spectrometry Determination of dissociation constants for oligonucleotide: Serum albumin complexes.J Am Chem Soc117 (43): 10765–10766
Joos RW, Hall WH (1969) Determination of binding constants of serum albumin for penicillin.J Pharmacol Exp Ther166: 113
Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proc Natl Acad Sci USA88: 7595–7599
Srinivasan SK, Iversen P (1995) Review ofin vivopharmacokinetics and toxicology of phosphorothioate oligonucleotides.J Clin Lab Anal9: 129–137
Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST (1994) Pharmacokinetics of a14C-labeled phosphorothioate oligonucleotide ISIS 2105, after intradermal administration to rats.J Pharm Exp Ther269: 89–94
Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin MJ, Leeds J, Barr WH (1994) A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.Clin Pharm Therap56: 641–646
Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke S (1993) Disposition of the14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.J PharmacolExpTher267: 1181–1190
Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL (1994) Biodistribution and metabolism of internally3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.Mol Pharmacol45: 932–943
Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis-Farrar KM, Stecker KK, Martin MJ, Crooke RM (1998)In vivodistribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.J Pharmacol Exp Ther286: 447–458
Sands H, Gorey-Feret LJ, Ho SP, Bao Y, Cocuzza AJ, Chidester D, Hobbs FW (1995) Biodistribution and metabolism of internally3H-labeled oligonucleotides II 3’,5’-blocked oligonucleotides.Mol Pharmacol47: 636–646
Crooke ST, Bennett CF (1996) Progress in antisense oligonucleotide therapeutics.Ann Rev Pharmacol Toxicol36: 107–129
Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ (1997) Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice.Antisense Nucleic Acid Drug Dev7(5): 473–481
Levin AA, Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M, Templin MV, Henry SP (1998) Toxicity of oligodeoxynucleotide therapeutic agents. In:Handbook of experimental pharmacology: Antisense research and application.Springer-Verlag, Berlin, Heidelberg.
Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett F, Crooke ST (1997) Immune stimulation — a class effect of phosphorothioate oligodeoxynucleotides in rodents.Anti-cancer Drug Design12(5): 421–432
Muccioli C, Goldstein DA, Johnson DW, Perez JE, Mora-Duarte JF, Sheppard JD, Man-sour SE, Chan CK, Palestine AG, Grillone LR et al (1998) Fomivirsen safety and efficacy in the treatment of CMV retinitis: A Phase 3, controlled, multicenter study comparing immediate versus delayed treatment. In:5th Conference on retroviruses and opportunistic infectionsSheraton Chicago Hotel, Chicago, IL
Gewirtz AM (1997) Developing oligonucleotide therapeutics for human leukemia.Anti-Cancer Drug Design12(5): 341–358
Sikic GI, Yuen AR, Halsey J, Fisher GA, Pribble JP, Smith RM, Geary R, Dorr A (1997) A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521) delivered by twenty-one day continuous intravenous infusion. In:33rd Annual Meeting of the American Society of Clinical OncologyDenver, CO
O’Dwyer PJ, Stevenson JP, Gallagher M, Mitchell E, Friedland D, Rose L, Cassella A, Holmlund J, Dean N, Dorr A et al (1998) Phase I/phamracokinetic/pharmacodynamic trial of raf-1 antisense ODN (ISIS 5132, CGP 69846A). In:34th Annual Meeting of the American Society of Clinical OncologyLos Angeles, CA
Muccioli C, Goldstein DA, Perez JE, Mora-Duarte JF, Sheppard JD, Mansour SE, Chan CK, Palestine AG, Holland GN, Pelkey WL et al (1998) Safety and efficacy of fomivirsen in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment. In:8th international Congress on Infectious DiseasesBoston, MA
Glover JM, Leeds JM, Mant TGK, Amin D, Kisner D, Zuckerman J, Geary RS, Levin A, Shanahan JWR (1997) Phase 1 safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).J Pharmacol Exp Ther282: 1173–1180
Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Rothlein RA, Mainolfi E, Tami JA, Bennett CF, Kisner DL, Shanahan WR (1998) A placebo-controlled trial of ISIS 2302 (ICAM-1 antisense oligonucleotide) in the treatment of steroid-dependent Crohn’s disease.Gastroenterology114: 1133–1142
Shanahan WR (1998) Properties of ISIS 2302, an inhibitor of intercellular adhesion molecule-1, in humans. In: ST Crooke (ed):Handbook of experimental pharmacology: Antisense research and application.Springer-Verlag, Berlin, Heidelberg, 499–524
Milligan JF, Matteucci MD, Martin JC (1993) Current concepts in antisense drug design.J Med Chem36: 1923–1937
Sanghvi YS, Cook PD (1993) Towards second-generation synthetic backbones for anti-sense oligonucleosides. In: CK Chu, DC Baker (eds):Nucleosides nucleotides as antiviral and antitumor agents.Plenum Press, New York, 309–322
Beaucage SL, Iyer RP (1993) The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications.Tetrahedron49: 6123–6194
Sanghvi YS, Cook PD (1994) Carbohydrates: Synthetic methods and applications in antisense therapeutics: An overview. In: YS Sanghvi, PD Cook (eds):Carbohydrate modifications in antisense research. ACS Symposium Series No 580, American Chemical Society: Washington, DC 1–22
Sagi J, Szemzo A, Ebinger K, Szabolocs A, Sagi G, Ruff E, Otvos L (1993) Base-modified oligodeoxynucleotides I Effect of 5-alkyl, 5-(1-alkenyl) and 5-(1-alkynyl) substitution of the pyrmidines on duplex stability and hydrophobicity.Tetrahedron Letters34: 2191–2194
Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.Science260 (5113): 1510–1513
Iribarren AM, Sproat BS, Neuner P, Sulston I, Ryder U, Lamond AI (1990) 2’-O-alkyl oligoribonucleotides as antisense probes.Proc Natl Acad Sci USA87(19): 7747–7751
Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C, Cook PD (1993) Uniformly modified 2’-deoxy-2’-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.J Med Chem36: 831–841
Lesnik EA, Guinosso CJ, Kawasaki AM, Sasmor H, Zounes M, Cummins LL, Ecker DJ, Cook PD, Freier SM (1993) Oligodeoxynucleotides containing 2’-O-modified adenosine: Synthesis and effects on stability of DNA: RNA duplexes.Biochemistry32: 7832–7838
Martin P (1995) New access to 2’-O-alkylated ribonucleosides and properties of 2’-Oalkylated oligoribonucleotides.Helv Chim Acta78: 486–504
Cummins LL, Owens SR, Risen LM, Lesnik EA, Freier SM, McGee D, Guinosso CJ, Cook PD (1995) Characterization of fully 2’-modified oligoribonucleotide hetero-and homoduplex hybridization and nuclease sensitivity.Nucleic Acids Res23 (11): 2019–2024
Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM (1993) Evaluation of 2’ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression.J Biol Chem268: 14514–14522
Agrawal S, Mayrand SH, Zamecnik PC, Pederson T (1990) Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.Proc Natl Acad Sci USA87: 1401–1405
Lamond AI, Barabino S, Blencowe BJ, Sproat B, Ryder U (1990) Studying pre-mRNA splicing using antisense 2-OMe RNA oligonucleotides.Mol Biol Rep14: 201
Miller PS, McParland KB, Jayaraman K, Ts’o P (1981) Biochemical and biological effects of nonionic nucleic acid methylphosphonates.Biochemistry20: 1874–1880
Miller PS, Ts’o P (1987) A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression).Anti-Cancer Drug Design2: 117–128
Miller PS (1991) Oligonucleoside methylphosphonates as antisense reagents.BioTechnology9: 358–362
Arnold LJ (1995) The development of oligonucleotides containing chirally pure methylphosphonates as therapeutic agents.Antisense Res Dey5: 108
Vasseur JJ, Debart F, Sanghvi YS, Cook PD (1992) Oligonucleosides: synthesis of a novel methylhydroxylamine-linked nucleoside dimer and its incorporation into anti-sense sequences.J Am Chem Soc114 (10): 4006–4007
De Mesmaeker A, Lebreton J, Waldner A, Fritsch V, Wolf RM, Freier SM (1993) Amides as substitute for the phosphodiester linkage in antisense oligonucleotides.Synlett10: 733–736
Jones RJ, Lin K-Y, Milligan JF, Wadwani S, Matteucci MD (1993) Synthesis and binding properties of pyrimidine oligodeoxynucleoside analogs containing neutral phosphodiester replacements The formacetal and 3’-thioformacetal internucleoside linkages.J Org Chem58: 2983–2991
Crooke ST (1995)Therapeutic applications of oligonucleotides.RG Landes Company, Austin, 138
Buchardt O, Egholm M, Berg RH, Nielsen PE (1993) Peptide nucleic acids (PNA) and their potential applications in medicine and biotechnology.Trends BioTechnology11: 384–386
Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules.Nature365: 566–568
Stirchak EP, Summerton JE, Weller DD (1989) Uncharged stereoregular nucleic acid analogs: 2 Morpholino nucleoside oligomers with carbamate internucleotide linkages.Nucleic Acids Research17: 6129–6141
Letsinger RL, Zhang GR, Sun DK, Ikeuchi T, Sarin PS (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture.Proc Natl Acad Sci USA86: 6553–6556
Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A, Silverman RH (1993) Targeting RNA for degradation with a (2’-5’)oligoadenylate-antisense chimera.Proc Natl Acad Sci USA90: 1300–1304
Manoharan M, Johnson LK, Bennett CF, Vickers TA, Ecker DJ, Cowsert LM, Freier SM, Cook PD (1994) Cholic acid-oligonucleotide conjugates for antisense applications.Bioorganic & Medicinal Chemistry Letters4: 1053–1060
Manoharan M, Tivel KL, Andrade LK, Mohan V, Condon TP, Bennett CF, Cook PD (1995) Oligonucleotide conjugates: Alteration of the pharmacokinetic properties of anti-sense agents.Nucleosides Nucleotides14 (3–5): 969–973
Harel-Bellan A, Durum S, Muegge K, Abbas AK, Farrar WL (1988) Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in TH1 and Th2 helper T cell clones.J Exp Med168: 2309–2318
Zubiaga AM, Munoz E, Huber BT (1991) Production of IL-1 alpha by activated Th type 2 cells Its role as an autocrine growth factor.J Immunol146: 3849–3856
Miles SA, Rezai AR, Salazar-Gonz lez JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T et al (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.Proc Natl Acad Sci USA87: 4068–4072
Levy Y, Tsapis A, Brouet J-C (1991) Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.J Clin Invest88: 696–699
Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM (1993) IL-8 produced by human malignant melanoma cellsin vitrois an essential autocrine growth factor.J Immunol151: 2667–2675
Birchenall-Roberts MC, Ferrer C, Ferris D, Falk LA, Kasper J, Gretchen W, Ruscetti FW (1990) Inhibition of murine monocyte proliferation by a colony-stimulating factor-1 antisense oligodeoxynucleotide Evidence for autocrine regulation.J Immunol145: 3290–3296
Fujiwara T, Grimm EA (1992) Specific inhibition of interleukin 10 gene expression by an antisense oligonucleotide: Obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells.Cancer Res52: 4954–4959
Maier JAM, Voulalas P, Roeder D, Maciag T (1990) Extension of the life-span of human endothelial cells by an interleukin-1a antisense oligomer.Science249: 1570–1574
Garfinkel S, Haines DS, Brown S, Wessendorf J, Gillespie DH, Maciag T (1992) Inter-leukin-la mediates an alternative pathway for the antiproliferative action of poly(I-C) on human endothelial cells.J Biol Chem267: 24375–24378
Benbernou N, Matsiota-Bernard P, Guenounou M (1993) Effect of cytokine-specific antisense oligonucleotides on the immunoglobulin production by rat spleen cellsin vitro. Biochimie75: 55–61
Benbernou N, Matsiota-Bernard P, Guenounou M (1993) Antisense oligonucleotides to interleukin-4 regulate IgE and IgG2a production by spleen cells from Nippostrongylus brasiliensis-infected rats.Eur J Immunol23: 659–663
Burch RM, Mahan LC (1991) Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.J Clin Invest88: 1190–1196
Bennett CF, Condon T, Grimm S, Chan H, Chiang M-Y (1994) Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides.J Immunol152: 3530–3540
Segal GM, Smith TD, Heinrich MC, Ey FS, Bagby GC (1992) Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides.Blood80: 609–616
Thomae KR, Geller DA, Billiar TR, Davies P, Pitt BR, Simmons RL, Nakayama DK (1993) Antisense oligodeoxynucleotide to inducible nitric oxide synthase inhibits nitric oxide synthesis in rat pulmonary artery smooth muscle cells in culture.Surgery114: 272–277
Maier JAM, Ragnotti G (1993) An oligomer targeted against protein kinase C prevents interleukin-1 induction of cyclooxygenase expression in human endothelial cells.Exp Cell Res205: 52–58
Dean NM, McKay R, Condon TP, Bennett CF (1994) Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.J Biol Chem269: 16416–16424
Narayan R, Higgins KA, Perez JR, Coleman TA, Rosen CA (1993) Evidence for differential functions of the p50 and p65 subunits of NF-KB with a cell adhesion model.Mol Cell Biol13: 3802–3810
Sokoloski JA, Sartorelli AC, Rosen CA, Narayan R (1993) Antisense oligonucleotides to the p65 subunit of NF-kappaB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes.Blood82: 625–632
Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LLK (1993)In vivoanticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.Blood81: 3271–3276
Nyce JW, Metzger WJ (1997) DNA antisense therapy for asthma in an animal model.Nature385 (6618): 721–725
Nyce JW (1997) Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases.Exp Opin Invest Drugs6 (9): 1149–1156
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Basel AG
About this chapter
Cite this chapter
Crooke, S.T. (2000). Oligonucleotide-based drugs in the control of cytokine synthesis. In: Higgs, G.A., Henderson, B. (eds) Novel Cytokine Inhibitors. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8450-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8450-1_4
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9572-9
Online ISBN: 978-3-0348-8450-1
eBook Packages: Springer Book Archive